These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 19638466

  • 1. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
    Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY.
    Clin Cancer Res; 2009 Aug 01; 15(15):4838-46. PubMed ID: 19638466
    [Abstract] [Full Text] [Related]

  • 2. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

  • 3. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium.
    Benetti A, Berenzi A, Gambarotti M, Garrafa E, Gelati M, Dessy E, Portolani N, Piardi T, Giulini SM, Caruso A, Invernici G, Parati EA, Nicosia R, Alessandri G.
    Cancer Res; 2008 Oct 15; 68(20):8626-34. PubMed ID: 18922939
    [Abstract] [Full Text] [Related]

  • 4. Tumor endothelial cells join the resistance.
    Dudley AC, Klagsbrun M.
    Clin Cancer Res; 2009 Aug 01; 15(15):4787-9. PubMed ID: 19638456
    [Abstract] [Full Text] [Related]

  • 5. Isolated tumor endothelial cells maintain specific character during long-term culture.
    Matsuda K, Ohga N, Hida Y, Muraki C, Tsuchiya K, Kurosu T, Akino T, Shih SC, Totsuka Y, Klagsbrun M, Shindoh M, Hida K.
    Biochem Biophys Res Commun; 2010 Apr 16; 394(4):947-54. PubMed ID: 20302845
    [Abstract] [Full Text] [Related]

  • 6. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
    Zeng KW, Li N, Dong X, Ma ZZ, Jiang Y, Jin HW, Tu PF.
    Eur J Pharmacol; 2013 Aug 15; 714(1-3):261-73. PubMed ID: 23684542
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Phenotypic and functional characteristics of endothelial cells derived from human liver cancer].
    Wu LQ, Zhang WJ, Ye LY, Yang ZH, Lou JN.
    Zhonghua Zhong Liu Za Zhi; 2007 Jun 28; 29(6):419-23. PubMed ID: 17974273
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.
    Cell Signal; 2014 May 28; 26(5):1030-9. PubMed ID: 24486412
    [Abstract] [Full Text] [Related]

  • 16. [The role of angiogenesis in renal carcinoma].
    Bussolati B, Satolli MA, Camussi G.
    G Ital Nefrol; 2008 May 28; 25(3):297-305. PubMed ID: 18473301
    [Abstract] [Full Text] [Related]

  • 17. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y.
    Biomaterials; 2015 Oct 28; 67():194-203. PubMed ID: 26218745
    [Abstract] [Full Text] [Related]

  • 18. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL.
    J Pharmacol Exp Ther; 2011 Apr 28; 337(1):155-61. PubMed ID: 21205925
    [Abstract] [Full Text] [Related]

  • 19. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
    Kuczynski EA, Kerbel RS.
    Chin J Cancer; 2016 Nov 25; 35(1):97. PubMed ID: 27887628
    [Abstract] [Full Text] [Related]

  • 20. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
    Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.
    J Natl Cancer Inst; 2016 Aug 25; 108(8):. PubMed ID: 27059374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.